Your Source for Venture Capital and Private Equity Financings

OncoPep Pulls In $11M Series D Round

2021-12-09
CAMBRIDGE, MA, OncoPep, a developer of transformative immunotherapeutics, announced $11 million in Series D funding.
The Series D was led by Tera Science and Kukje Pharma with participation from SX Company and CrystalBioScience.

The Series D funding will enable OncoPep to continue its clinical trials and advance preclinical development of novel pipeline agents. OncoPep's lead investigational candidate, PVX-410, is a cancer vaccine in clinical development for smoldering multiple myeloma (SMM) and triple negative breast cancer (TNBC).

OncoPep, Inc. is developing novel immunotherapeutics to prevent the progression of cancer, extend survival, and restore the quality of life of patients. OncoPep's lead program, PVX-410, is an investigational, multi-peptide therapeutic vaccine being evaluated in treating multiple myeloma and triple-negative breast cancer by stimulating an immune response against cancer cells.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors